The contribution of the thymus-dependent pathway and thymus-independent pathways for T cell regeneration after BMT in children is still unclear. We analyzed the kinetics of T cell regenerative pathways after allogeneic BMT. The number of CD4 
T cell populations recover via thymus-dependent and thymus-independent pathways after T cell depletion following chemotherapy or BMT. CD4 + CD45RA + T cells are suggested to be thymus-dependent because (1) CD4
+ T cells express the CD45RA antigen when they are exported from the thymus; 1-2 (2) thymectectomized hosts fail to reconstitute CD4 + CD45RA + T cells for a long period after BMT compared with thymus-bearing hosts; 3 (3) reconstitution of CD4 + CD45RA + T cells coincides with the enlargement of thymus size after high-dose chemotherapy; 4 and (4) an inverse relationship between patients' ages and the reconsti- + CD45RA + T cells is observed after intensive chemotherapy. 4 Thymus-independent T cell regeneration after BMT includes extrathymic differentiation, and peripheral expansion of mature T cells derived from donor bone marrow cells.
5-6 CD8 + CD28 − T cells appear to regenerate thymusindependently, since CD8 + CD28 − T cells reconstitute rapidly after BMT in spite of the therapy-related thymic atrophy. 7 
V␥9
+ V␦2 + T cells, constituting a minor population in the peripheral blood of healthy individuals, differentiate extrathymically. 8 
V␣24 + T cells represent a human homologue of V␣14
+ T cells which differentiate extrathymically in mice.
9,10 CD8␣/␣ + T cells may also differentiate extrathymically in humans because CD8␣/␣ + T cells reside in intestinal mucosa in nude mice, [11] [12] [13] and a large number of CD8␣/␣ + T cells was identified in the human fetal intestine. 14 As little is known about the relative contribution of the three pathways to T cell regeneration after allogeneic BMT, we analyzed T cell regeneration using putative phenotypic markers of thymus-dependent pathway (CD4 + CD45RA + T cells) and thymus-independent pathways (V␥9 + V␦2 + T cells, V␣24
+ T cells, CD8␣/␣ + T cells and CD28 − T cells) after allogeneic BMT in children.
Materials and methods

Patients
Twelve children with acute leukemia or myelodysplastic syndrome who underwent allogeneic BMT were eligible for the study (Table 1 ). Age at BMT was from 0.7 to 16 years. Total body irradiation (TBI) was included in conditioning regimens in three children. Father or mother was chosen as the donor for BMT in two, and siblings were chosen in 10. All children received methotrexate (MTX) and/or cyclosporine (CsA) as prophylaxis for GVHD. Acute GVHD appeared in seven children: grade I in three, grade II in three, and grade III in one. Two patients (UPN8 and UPN9) suffered from limited and extensive chronic GVHD, respectively. Engraftment was confirmed within 28 days after bone marrow transplantation in all cases. The chimerism analysis was performed by the detection of sex-chromosomes in sex-mismatched bone marrow transplantation, red blood cell antigen differences, or variable number of tandem repeats (VNTR). Blood cells from the patients after UPN = unique patient number; RA = refractory anemia; CR1 = first complete remission; CR2 = second complete remission; Rel = relapse; BU = busulfan; L-PAM = melphalan; TBI = total body irradiation; CY = cyclophosphamide; CA = cytosine arabinoside; MTX = methotrexate; CsA = cyclosporine A. a HLA-matched. b HLA-1-locus mismatched.
BMT originated completely from the donor cells in all cases (data not shown). All children were alive after BMT; one patient (UPN11) relapsed, but had been in remission until the completion of the study.
Flow cytometric analysis
Heparinized venous blood samples were collected from each patient at 1, 2, 3 and 6 months after BMT. Threecolor immunofluorescence analysis was performed with EPICS XL (Coulter, Hialeah, FL, USA) as follows. Whole white blood cells were stained with appropriate amounts of FITC-, PE-and PE-Cy5-conjugated monoclonal antibodies (mAbs) simultaneously at 4°C for 15 min. Red blood cells were then lyzed with ammonium chloride. The cells were washed twice and suspended in phosphate-buffered saline. Analysis was performed on cells after gating for lymphocytes by forward and side scatters. FITC-conjugated anti-CD3, anti-HLA-DR, anti-CD45RA, PE-conjugated anti-CD3, anti-CD4, anti-CD8 ␤ chain, PE-Cy5-conjugated anti-CD8 ␣, chain and anti-pan ␥/␦ mAb were purchased from Coulter (Miami, FL, USA). PE-conjugated anti-CD28 mAb and anti-CD45RO mAb were purchased from Becton Dickinson (San Diego, CA, USA), and Nichirei (Tokyo, Japan), respectively. CD8␣/␣ + T cells were determined by 15 An isotype control antibody was also used in each experiment. As control values, lymphocyte subsets were analyzed in nine healthy children. The age distribution of healthy children was almost identical to that of 12 patients.
Statistical analyses
One-way and two-way analyses of variance were used to test the equality of adjusted means of five groups (1, 2, 3 and 6 months after BMT, and healthy control). A difference in the number of T cells or T cell subsets after BMT between the two groups was analyzed by Mann-Whitney's U-test. The pairwise multiple comparison test was performed using the method of Bonferroni adjustment when analysis of variance showed P Ͻ 0.05. The correlation between the numbers of CD8␣/␣ + and CD28 − T cells were analyzed by Spearman's rank sum test. Clinical parameters (patient's age, sex, duration from onset to BMT, donor's age, conditioning regimen, presence of acute GVHD) in patients who showed high levels of CD8␣/␣ + T cells after BMT were also compared with those in patients who showed no increase of these cells by Wilcoxon's rank sum test. All statistical analyses were conducted by the BMDP Statistical Software Package Program (BMDP Statistical Software Inc, Los Angeles, CA, USA) on the Sun Microsystems SPARC station 20 (Mountain View, CA, USA).
Results
The numbers of different T cell subpopulations in each patient and healthy children were plotted in Figure 1 . The number of CD3 + cells was significantly lower at 1 month than in controls (P Ͻ 0.05), and gradually increased to the normal level. The number of T cell receptor (TCR) ␥/␦ + T cells was comparable to that of healthy children 2-6 months after BMT. The number of CD4 + T cells was significantly low until 2 months after BMT (P Ͻ 0.05), whereas the number of CD8 + T cells immediately increased and reached a normal level 2 months after BMT.
The kinetics of thymus-dependent and -independent T cells was analyzed. As shown in Figures 2 and 3 , the number of thymus-dependent CD4 + CD45RA + T cells was very low until 3 months after BMT and it began to increase at 6 months but still lower than that of healthy children (P Ͻ 0.05).
Since there was a close correlation between the numbers of CD28
− T cells and CD8 + CD28 − T cells in a preliminary study (r 2 = 0.803, P Ͻ 0.001, Spearman's rank sum test) and a majority of T cells were CD8
+ shortly after BMT, we employed the number of CD3
+ CD28 − cells as one of 
CD45RA
+ cells remained low in number (a).
the markers of thymus-independent pathways. The numbers of CD3 + CD28 − and CD3 + CD8␣/␣ + cells began to increase shortly after BMT beyond the levels of healthy children in some patients (Figures 2 and 3 ). There was a significant inverse correlation between the percentages of CD4 + CD45RA + and CD28 − T cells at 1 month after BMT in these children (P Ͻ 0.05, Figure 4a ). In addition, a significant positive correlation between the percentages of CD28 − and CD8␣/␣ + T cells at 2 and 3 months after BMT (P Ͻ 0.05, Figure 4b ). Increased numbers of both CD28 
Months
Months Months vs 1700/l for CD3 + cells: P Ͻ 0.01, 10.6 vs 41.4/l for CD4 + CD45RA + T cells: P Ͻ 0.05, 21.7 vs 392/l for CD8␣␣ + T cells: P Ͻ 0.01, 217 vs 1560/l for CD28 − T cells: P Ͻ 0.05), suggesting the strong influence of GVHD on both thymus-dependent and thymus-independent T cell recovery. We could not assess the effects of infection because clinical evidence of infection such as CMV infection was not detected in all patients. Eight patients showed increased numbers of CD8␣/␣ + T cells at different times after BMT; three patients (UPN4, 5, 12) at 2 months, three patients (UPN3, 7, 11) at 3 months, and three patients (UPN1, 4, 8) at 6 months. Clinical parameters which will influence on the number of CD8␣/␣ + T cells after BMT were analyzed: the mean age (11.0 years) at BMT was higher in patients with a high level of CD8␣/␣ + T cells than that (5.2 years) without the increase of these cells, which was marginally significant by the statistical analysis (P = 0.063), suggesting the influence of thymic function on the regenerative pathways.
Discussion
T cell reconstitution after BMT does not resemble T cell development in early life. 10 Post-transplant peripheral expansion of mature T cells derived from donor bone marrow cells, and thymic insufficiency in patients after BMT would be the major factors responsible for the difference. [4] [5] [6] The evidence of transfer of antigen-specific T cell immunity from the donors to recipients as early as 30 days after BMT supports post-transplant peripheral expansion of the mature T cells in early stages after BMT. [16] [17] [18] [19] Recipient age, chemotherapy, radiation, corticosteroids, infection, and GVHD might be the main factors that can cause thymic atrophy and impair thymus-dependent T cell development after BMT. 20 After allogeneic BMT, the increases in the numbers of T cells expressing the CD4 + CD45RA + phenotype, a putative marker of thymusdependent pathway, were much slower in our study, than those observed after high-dose chemotherapy. 4 In addition, we think it takes more than a year for the thymus-dependent T cells to become the dominant population after BMT, even in young patients with a functional thymus because the numbers of the thymus-dependent population 12 months after BMT in three cases were not significantly higher than those 6 months after BMT (data not shown). The delay in T cell regeneration in patients after BMT compared with that after chemotherapy may be due to the drugs used for GVHD prophylaxis and in seven of the 12 cases, the emergence of acute GVHD which affects thymic function. In fact, T cell recovery was markedly suppressed both in the thymus-dependent and thymus-independent pathways in patients who had GVHD.
It is clear that certain T cell subsets mature extrathymically in mice 10, 12, 14 and humans. 8, 9 From our study, it is not likely that extrathymic differentiation plays a major role in T cell recovery after allogeneic BMT because V␥9 − T cells contain a large proportion of CD8␣/␣ + T cells 21 and there was a close correlation between the numbers of CD28 − and CD8␣/␣ + T cells in the present study.
In addition to the post-BMT state, [22] [23] [24] expansion of CD8 + CD28 − T cells has also been observed in several other clinical conditions with thymic insufficiency: HIV infection 25 and aging. 26, 27 The inverse correlation between the numbers of CD4 + CD45RA + and CD28 − T cells at the early stage after BMT supported the fact that CD28 − T cells were derived from the thymus-independent pathway. Additional evidence to support this hypothesis is that the rapid increase in CD28 − T cells occurred less than 3 months after BMT whilst thymus-dependent T cell regeneration does not usually occur after mature T cell depleted BMT. 28, 29 Since thymus-dependent and extrathymic T cell differentiation made minimal contributions to T cell recovery before 3 months after BMT, it is possible that thymus-independent peripheral expansion, as a result of impaired thymic function, might be a major T cell regeneration pathway shortly after allogeneic BMT. The peripheral expansion of T cells derived from donor bone marrow cells may occur mainly as a result of allo-stimulation after BMT, as it has been clearly demonstrated using transgenic mice that antigen recognition is required for peripheral expansion. 30 Better markers for discriminating the T cell-dependent and T cell-independent populations will further facilitate the understanding of the regenerative pathways for T cells after BMT.
